Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors.

Both Court Square and MTS Health are private equity firms.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

All the entities involved in the acquisition are based in the US.

Quotient Sciences has acquired contract development and manufacturing organisation Pharmaterials.

This acquisition enables the drug development services organisation to expand its services in the UK.

Both Quotient Sciences and Pharmaterials are based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“PhoenixBio plans to acquire Canadian in-vivo research services provider KMT Hepatech for C$5.5m ($4.33m).”

Jinzi Ham plans to acquire a 37.14% stake in NovaBay Pharmaceuticals for $27.06m.

Jinzi Ham is a Chinese food production company, whereas NovaBay Pharmaceuticals is a US-based biopharmaceutical company.

PhoenixBio plans to acquire Canadian in-vivo research services provider KMT Hepatech for C$5.5m ($4.33m).

KMT Hepatech will become a subsidiary of the Japanese life-science company upon completion of the acquisition.

Arlington Capital Partners has acquired a majority stake in contract, development, and manufacturing organisation Grand River Aseptic Manufacturing (GRAM).

Both the companies involved are based in the US.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact